Eef Dirksen
Head, Analytical Development & Quality Control Byondis B.V.
After obtaining a PhD in biomolecular mass spectrometry in 2006, Eef Dirksen moved to Philips Research and in 2010, he was hired by MSD (Merck) in Oss, The Netherlands, where he managed a team focusing on the characterization of biopharmaceutical proteins. Here, Eef was, involved in the successful late-stage development of Keytruda®.
In 2015, Eef joined Byondis to work on elucidating the in vivo biotransformation of antibody-drug conjugates (ADCs). Currently, he is heading the Department of Analytical Development and Quality Control that is responsible for all analytical activities in support of early-stage CMC development of monoclonal antibodies and ADCs.
Seminars
Wrap up the two days of content with actionable insights to elevate your ADC process and analytics. Together with fellow attendees, discuss and debate the best ways to define ADC CQAs, undergo impurity characterisation and control, and energise bioassay development.
- Laying out how ADCs combine the strengths of small and large molecules, thereby posing novel analytical challenges
- Explaining how analytics are key in gauging the heterogeneity and complexity of ADCs
- Undergoing a multidisciplinary approach required to evaluate the impact on safety and efficacy of any (new) ADC impurities
